These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38598020)

  • 21. Oncogenic Properties of the Antisense lncRNA
    Esposito R; Esposito D; Pallante P; Fusco A; Ciccodicola A; Costa V
    Cancer Res; 2019 May; 79(9):2124-2135. PubMed ID: 30862713
    [No Abstract]   [Full Text] [Related]  

  • 22. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.
    Mesa C; Mirza M; Mitsutake N; Sartor M; Medvedovic M; Tomlinson C; Knauf JA; Weber GF; Fagin JA
    Cancer Res; 2006 Jul; 66(13):6521-9. PubMed ID: 16818623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
    Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
    Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation Between the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated with Hashimoto's Thyroiditis, BRAF V600E Gene Mutation, and RET Gene Rearrangement.
    Xie M; Xu ZX; Dai M; Zhu YY
    J Coll Physicians Surg Pak; 2024 Apr; 34(4):445-450. PubMed ID: 38576288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.
    Musholt TJ; Staubitz JI; Antonio Cámara RJ; Musholt PB; Humberg D; Springer E; Schad A
    Eur J Surg Oncol; 2019 Jun; 45(6):1018-1024. PubMed ID: 30472213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
    Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
    Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of genetic mutations in thyroid cancer: a meta-analysis.
    Pak K; Suh S; Kim SJ; Kim IJ
    Thyroid; 2015 Jan; 25(1):63-70. PubMed ID: 25244593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components.
    Mochizuki K; Kondo T; Nakazawa T; Iwashina M; Kawasaki T; Nakamura N; Yamane T; Murata S; Ito K; Kameyama K; Kobayashi M; Katoh R
    Histopathology; 2010 Sep; 57(3):444-50. PubMed ID: 20840674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.
    Sadow PM; Heinrich MC; Corless CL; Fletcher JA; Nosé V
    Endocr Pathol; 2010 Jun; 21(2):73-9. PubMed ID: 20012784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.
    Ciampi R; Nikiforov YE
    Endocrinology; 2007 Mar; 148(3):936-41. PubMed ID: 16946010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.
    Pizzolanti G; Russo L; Richiusa P; Bronte V; Nuara RB; Rodolico V; Amato MC; Smeraldi L; Sisto PS; Nucera M; Bommarito A; Citarrella R; Lo Coco R; Cabibi D; Lo Coco A; Frasca F; Gulotta G; Latteri MA; Modica G; Galluzzo A; Giordano C
    Thyroid; 2007 Nov; 17(11):1109-15. PubMed ID: 17727338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer.
    Ming J; Liu Z; Zeng W; Maimaiti Y; Guo Y; Nie X; Chen C; Zhao X; Shi L; Liu C; Huang T
    Int J Clin Exp Pathol; 2015; 8(11):15155-62. PubMed ID: 26823860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics.
    Leeman-Neill RJ; Brenner AV; Little MP; Bogdanova TI; Hatch M; Zurnadzy LY; Mabuchi K; Tronko MD; Nikiforov YE
    Cancer; 2013 May; 119(10):1792-9. PubMed ID: 23436219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Invasive properties of papillary thyroid cancer with concurrent BRAF(V600E) mutation and rearranged during transfection proto-oncogene protein expression].
    Meng C; Gao J; Liang J; Liang ZY; Lin YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Feb; 35(1):64-8. PubMed ID: 23469793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer.
    Lin AJ; Samson P; DeWees T; Henke L; Baranski T; Schwarz J; Pfeifer J; Grigsby P; Markovina S
    Cancer Med; 2019 Jan; 8(1):437-446. PubMed ID: 30552739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RET polymorphisms might be the risk factors for thyroid cancer.
    Huang RX; Yang F
    Int J Clin Exp Pathol; 2015; 8(5):5793-7. PubMed ID: 26191299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of RET genetic polymorphisms and haplotypes with papillary thyroid carcinoma in the Portuguese population: a case-control study.
    Santos M; Azevedo T; Martins T; Rodrigues FJ; Lemos MC
    PLoS One; 2014; 9(10):e109822. PubMed ID: 25330015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population.
    Kang DY; Kim KH; Kim JM; Kim SH; Kim JY; Baik HW; Kim YS
    Thyroid; 2007 Nov; 17(11):1031-8. PubMed ID: 17900235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.